SUMMARY One gram N-benzoyl-L-tyrosyl PABA was orally administered to 24 controls, 15 patients with chronic exocrine pancreatic disease, 13 patients after an attack of acute pancreatitis, two patients with gluten-sensitive enteropathy, and 10 patients with biliary tract disease, peptic ulcer, or other pathology of the gastrointestinal tract. In the presence of chymotrypsin, PABA is split from the peptide and excreted in the urine. The amount of PABA excreted serves as a parameter of exocrine pancreatic function. In 51 patients, exocrine pancreatic secretion was also assessed by the Lundh test. In the control group a mean of 59-6 12-2% (mean ± 2 SD) of the peptide-PABA was excreted over a period of six hours. PABA excretion in exocrine pancreatic deficiency was significantly less (p < 0.001) than in controls. (Fig. 1) . In the small bowel, in the presence of chymotrypsin, the peptide is split resulting in the liberation of PABA, which is rapidly absorbed from the gut, undergoes conjugation in the liver, and is excreted in the urine. The amount of PABA recovered in the urine during a certain time is used as an index of exocrine pancreatic function. The test has been used for the assessment of exocrine pancreatic deficiency in protein deficient patas monkeys 
In 1972 Imondi et al. reported reliable results in animals with a pancreatic function test involving the oral administration of a chymotrypsin-labile peptide which contains para-aminobenzoic acid (PABA) as a tracer group (Fig. 1 ). In the small bowel, in the presence of chymotrypsin, the peptide is split resulting in the liberation of PABA, which is rapidly absorbed from the gut, undergoes conjugation in the liver, and is excreted in the urine. The amount of PABA recovered in the urine during a certain time is used as an index of exocrine pancreatic function. The test has been used for the assessment of exocrine pancreatic deficiency in protein deficient patas monkeys subjects, and 11 patients (five men and six women aged 16 to 58 years) without organic disease of the gastrointestinal tract served as controls. Pancreatic disease was excluded after a thorough clinical examination and by the Lundh test in eight normal subjects and in all control patients. The interval between the PFT and the Lundh tests did not exceed one month in the normal subjects and 6 5 months in the control patients. The sequence of the tests was chosen randomly for the normal subjects only. (Lundh, 1962) were allowed after the six hour urine collection had been completed. A one hour control collection of urine was taken before the administration of the peptide. After ingestion of the test meal, urine collections were made at the time stated in each experiment. The concentration of aromatic amines was determined by the Bratton-Marshall method as modified by Smith et al. (1945) by means of a Vitatron Digital Concentration Photometer at 546 nm wave length.
Results were highly reproducible (r = 0-998; p < 0-001). Background urinary aromatic amines were negligible and were not corrected for unless there was an obvious contamination by drugs containing other para-amino-benzoyl derivates such as sulphonamides and sulphonyl urea compounds. The term PABA is used in this study to denote aromatic amines since the bulk of the urinary aromatic amines originated from orally administered peptide-PABA. Results were conveyed as percentage of PABA recovered in the urine as compared with the applied dose.
Since the peptide was not available on the market for use in man, it was synthesized for this investigation. The substance obtained was equivalent in purity to that described by de Benneville et al. 243-244'C and 87.00 respectively). The peptide was used in the form of its sodium salt, which, in contrast with its acid form, is highly water soluble. Administration of the peptide to rats and mice did not produce any signs of acute toxicity with respect to the amount applied to man.
The peptide was given in a dose of 1 g, which is equivalent to 320 mg PABA (approximately 5 mg PABA per kg body weight used by Imondi et al., 1972 in dogs) .
LUNDH TEST
The Lundh test, a routine procedure in our department, was performed as described by Aenishaenslin et al. (1973) and Mottaleb et al. (1973) . The trypsin mean concentration (TMC) was determined in two hour collections of duodenal contents according to the method of Wiggins (1967) and expressed in ,tEq H+/min/ml (IU). A TMC below 8-8 ,uEq H+/min/ml was considered abnormal (Aenishaenslin et al., 1973; Remington and Schork (1970 Reproducibility of the PFT was tested in 10 subjects, of whom nine were controls and one was a patient with exocrine pancreatic deficiency. A significant correlation was found among replicate tests (y = 4-9 + 0-895 x, r = 0-899, p < 0-001).
For comparison, 320 mg pure para-aminobenzoic acid-equivalent to 1 g peptide-was administered orally to five normal subjects in a test meal and the extent of its urinary excretion measured at two hour intervals. Only a six hour collection of urine was performed in another normal subject. A mean of 75-7 ± 7-5% (mean ± SD) of the applied PABA was excreted by the six normal subjects in six hours, producing a normal range from 60-7 to 90-7%. Excretion of orally administered pure PABA in the first two hours significantly (p < 0-005) exceeded the excretion after ingestion of the peptide.
PATIENTS WITH CHRONIC PANCREATIC DISEASE
Fifteen patients with proven chronic pancreatic disease (Fig. 2) and exocrine pancreatic deficiency excreted significantly less PABA than the control group (p < 0-001; Fig. 2 ). With the exception of one case (E.Z., Table 1 ) the results were all well below 47%, the lower limit of normal calculated from the control group. Patient E.Z. underwent total pancreatectomy for persistent pain. On operation a cystic tumour of the fibrosed head of the pancreas was found. Histologically, the inflammation was localized to the head, with normal tissue in the body and tail. The PFT dropped to 3 9% after the operation.
Pure para-aminobenzoic acid was administered to one patient of this group and the amount excreted was within the normal range (patient C. M., Table 1 ).
Thus, any possible cause for the decreased excretion of PABA arising from disturbances of absorption, metabolism, and renal excretion of PABA could be excluded.
In the group with exocrine pancreatic deficiency, a significant correlation between PFT and Lundh test results was observed (r = 0-681, P < 0 05).
PATIENTS WITH ACUTE PANCREATITIS
Patients with an attack of acute pancreatitis were not tested until symptoms had subsided and pancreatic enzymes in blood and urine had returned to normal (Fig. 2) . The results showed a wide spectrum ranging from normal to abnormal values, both for PFT and Lundh test. One patient showed an abnormal result of the Lundh test just after the attack, one year before the present investigation. His exocrine pancreatic function recovered, as was shown by the PFT and the repeat Lundh test. Recovery of the PFT was also noted in two other patients during follow-up.
PATIENTS WITH NON-PANCREATIC DISEASE
Of the two patients with gluten sensitive enteropathy (Table 2) one had a normal PFT and Lundh test. This patient did not suffer from diarrhoea at the time of investigation, although intestinal biopsy showed subtotal villous atrophy. The other patient had a PFT test below normal. When pure paraaminobenzoic acid was given to this patient, its excretion was found to be slightly below the lower limit of normal (53-4 Y.). A period of severe diarrhoea due to dietary errors had immediately preceded the PFT test.
In Table 2 , patients with various gastrointestinal diseases other than sprue are presented. Only one (J.M.) had an abnormal function test. This patient had a history of heavy alcohol intake.
SIDE-EFFECTS
No side-effects or complications were noted in connection with the administration of the test peptide. In eight controls, glutamic oxaloacetic and glutamic pyruvic transaminases, alkaline phosphatase, bilirubin, sodium, potassium, urea, and Oral pancreatic function test creatinine were determined in the serum before administration of the peptide and at the end of PFT (Table 4 ). All results were within normal range.
Discussion
The present study reports the first experiences with the oral administration of N-benzoyl-L-tyrosyl-PABA as a new test of exocrine pancreatic function in man (PFT). The difference in urinary PABA excretion shown between controls and patients with exocrine pancreatic deficiency was highly significant. With one exception, no overlap of the individual results was observed. There was a significant correlation between Lundh test results and PFT in patients with pancreatic insufficiency. Although the PFT is based on chymotrypsin activity and the Lundh test evaluates trypsin secretion, the comparison of the results is justified, since a parallel secretion of the different pancreatic enzymes is reported by many authors (Burton et al., 1960; Dreiling and Janowitz, 1962; Lundh, 1962 (Aenishaenslin et al., 1973; Mottaleb et al., 1973) . It can be seen from the present PFT data in patients with exocrine pancreatic deficiency (Fig. 3) that the PFT is likely to be abnormal when the TMC is at the lower limit of normal set by Mottaleb et al. (1973) -that is, 6 ,uEq H+/min/ml.
In chronic liver disease, impaired excretion of PABA in high doses (Tabor et al., 1947) and decreased metabolism have been described (Deiss and Cohen, 1950 
